Press releases
- Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
- Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
- Fulgent Reports First Quarter 2024 Financial Results
- Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.80 |
---|---|
High | 17.80 |
Low | 17.70 |
Bid | 17.70 |
Offer | 18.00 |
Previous close | 18.00 |
Average volume | 14.44 |
---|---|
Shares outstanding | 29.92m |
Free float | 20.18m |
P/E (TTM) | -- |
Market cap | 571.25m USD |
EPS (TTM) | -5.57 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 18:32 BST.
More ▼